Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2006 1
2009 2
2011 3
2012 4
2013 1
2014 1
2015 2
2016 2
2017 3
2018 4
2019 3
2021 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for michael derosa
Search for Michael Dorosan instead (1 results)
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J. Reck M, et al. Among authors: derosa m. Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11. Eur J Cancer. 2019. PMID: 31195357 Free article. Clinical Trial.
Optimizing non-Newtonian fluids for impact protection of laminates.
Richards JA, Hodgson DJM, O'Neill RE, DeRosa ME, Poon WCK. Richards JA, et al. Among authors: derosa me. Proc Natl Acad Sci U S A. 2024 Mar 5;121(10):e2317832121. doi: 10.1073/pnas.2317832121. Epub 2024 Feb 27. Proc Natl Acad Sci U S A. 2024. PMID: 38412136 Free PMC article.
A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Shaw JW, Bennett B, Trigg A, DeRosa M, Taylor F, Kiff C, Ntais D, Noon K, King MT, Cocks K. Shaw JW, et al. Among authors: derosa m. Value Health. 2021 Nov;24(11):1651-1659. doi: 10.1016/j.jval.2021.05.022. Epub 2021 Aug 26. Value Health. 2021. PMID: 34711366 Free article.
Randomized Trial of Endoscopic or Open Vein-Graft Harvesting for Coronary-Artery Bypass.
Zenati MA, Bhatt DL, Bakaeen FG, Stock EM, Biswas K, Gaziano JM, Kelly RF, Tseng EE, Bitondo J, Quin JA, Almassi GH, Haime M, Hattler B, DeMatt E, Scrymgeour A, Huang GD; REGROUP Trial Investigators. Zenati MA, et al. N Engl J Med. 2019 Jan 10;380(2):132-141. doi: 10.1056/NEJMoa1812390. Epub 2018 Nov 11. N Engl J Med. 2019. PMID: 30417737 Clinical Trial.
Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study.
Reck M, Taylor F, Penrod JR, DeRosa M, Morrissey L, Dastani H, Orsini L, Gralla RJ. Reck M, et al. Among authors: derosa m. J Thorac Oncol. 2018 Feb;13(2):194-204. doi: 10.1016/j.jtho.2017.10.029. Epub 2017 Nov 10. J Thorac Oncol. 2018. PMID: 29129758 Free article. Clinical Trial.
27 results